Tobacco Control

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fagerstrom, K. O.
Right arrow Articles by Lunell, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fagerstrom, K. O.
Right arrow Articles by Lunell, E.

Tobacco Control, Vol 6, 311-316, Copyright © 1997 by BMJ Publishing Group


ARTICLES

Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?

KO Fagerstrom, R Tejding, A Westin and E Lunell
Pharmacia & Upjohn Consumer Healthcare, Helsingborg, Sweden. Karl.Olov.Fagerstrom@am.pnu.com

OBJECTIVE: To assess the effect of the various nicotine replacement therapies (NRT) on smoking reduction. DESIGN: During an initial sampling week, the subjects familiarised themselves with nicotine gum, patch, nasal spray, vaporiser (vapour inhaler) and sublingual tablet. A crossover design was used during the next four study weeks; during two of these weeks the subjects could select one nicotine replacement product of their choice to use, whereas during the other two they were randomly assigned a product to use. SUBJECTS: 143 men and women smoking an average of 22.6 (SD 7.0) cigarettes per day and exhibiting a Fagerstrom Tolerance Questionnaire (FTQ) score of 7.0 (SD 1.9). INTERVENTIONS: Subjects were asked to use as much NRT as they wished, yet to smoke enough to feel comfortable. MAIN OUTCOME MEASURES: Self- reported cigarette consumption, exhaled carbon monoxide (CO), withdrawal symptom score, cotinine plasma levels and motivation to quit were monitored over a period of five weeks. RESULTS: Self-reported smoking declined steadily over the five weeks, from 22.6 (SD 7.0) to 10.4 (SD 1.0) (P<0.001) cigarettes daily (54% decrease), with the biggest drop (37%) during the first product-sampling week. Smoking reduction was greater on average during the weeks when the subjects could choose their nicotine product than when products were assigned. CO readings decreased from 22.7 (SD 8.5) to 14.8 (SD 8.4) ppm (P<0.001) confirming a reduction in smoking (35% decrease), although cotinine levels remained steady, suggesting that subjects were titrating nicotine to their original levels. Withdrawal scores decreased over time (32% decrease, P<0.001), showing that there was no discomfort associated with the smoking reduction, and motivation to quit was enhanced by the treatment in most subjects (93%). CONCLUSIONS: NRT for aiding smoking reduction appeared to be safe, was associated with a clinically significant reduction in smoke exposure over a five-week follow up, and increased motivation to stop smoking. A smoking reduction procedure may help the very recalcitrant smoker gain confidence and increase the control over his/her smoking behaviour. More controlled research is needed to follow up these promising results.


This article has been cited by other articles:


Home page
JAMAHome page
N. S. Godtfredsen, E. Prescott, and M. Osler
Effect of Smoking Reduction on Lung Cancer Risk
JAMA, September 28, 2005; 294(12): 1505 - 1510.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. S. Simmons, J. E. Connett, M. A. Nides, P. G. Lindgren, E. C. Kleerup, R. P. Murray, W. M. Bjornson, and D. P. Tashkin
Smoking reduction and the rate of decline in FEV1: results from the Lung Health Study
Eur. Respir. J., June 1, 2005; 25(6): 1011 - 1017.
[Abstract] [Full Text] [PDF]


Home page
Tobacco ControlHome page
A M Joseph, D Hennrikus, M J Thoele, R Krueger, and D Hatsukami
Community tobacco control leaders' perceptions of harm reduction
Tob. Control, June 1, 2004; 13(2): 108 - 113.
[Abstract] [Full Text] [PDF]


Home page
J. Epidemiol. Community HealthHome page
N S Godtfredsen, M Osler, J Vestbo, I Andersen, and E Prescott
Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study
J. Epidemiol. Community Health, June 1, 2003; 57(6): 412 - 416.
[Abstract] [Full Text]


Home page
Am J EpidemiolHome page
N. S. Godtfredsen, C. Holst, E. Prescott, J. Vestbo, and M. Osler
Smoking Reduction, Smoking Cessation, and Mortality: A 16-year Follow-up of 19,732 Men and Women from the Copenhagen Centre for Prospective Population Studies
Am. J. Epidemiol., December 1, 2002; 156(11): 994 - 1001.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
N S Godtfredsen, J Vestbo, M Osler, and E Prescott
Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study
Thorax, November 1, 2002; 57(11): 967 - 972.
[Abstract] [Full Text] [PDF]


Home page
Tobacco ControlHome page
K. O Fagerström, J. R Hughes, T. Rasmussen, and P. W Callas
Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit
Tob. Control, September 1, 2000; 9(3): 327 - 333.
[Abstract] [Full Text]


Home page
BMJHome page
M. Thun and T. J Glynn
Improving the treatment of tobacco dependence
BMJ, August 5, 2000; 321(7257): 311 - 312.
[Full Text]


Home page
BMJHome page
C. T Bolliger, J.-P. Zellweger, T. Danielsson, X. van Biljon, A. Robidou, A. Westin, A. P Perruchoud, and U. Säwe
Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety
BMJ, August 5, 2000; 321(7257): 329 - 333.
[Abstract] [Full Text]


Home page
Health Educ BehavHome page
R. A. Windsor, C. Q. Li, N. R. Boyd Jr., and K. E. Hartmann
The Use of Significant Reduction Rates to Evaluate Health Education Methods for Pregnant Smokers: A New Harm Reduction Behavioral Indicator?
Health Educ Behav, October 1, 1999; 26(5): 648 - 662.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1997 by the BMJ Publishing Group Ltd.